Panandiker Kaya Kamlesh Pai - 10 Dec 2025 Form 4 Insider Report for LB PHARMACEUTICALS INC

Role: Chief Commercial Officer
Signature: /s/ Marc Panoff, Attorney-in-Fact
Issuer symbol: LBRX on Nasdaq
Transactions as of: 10 Dec 2025
Net transactions value: $0
Form type: 4
Filing time: 11 Dec 2025, 16:15:13 UTC
Previous filing: 18 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Pai Panandiker Kaya Kamlesh	Chief Commercial Officer	C/O LB PHARMACEUTICALS INC, ONE PENNSYLVANIA PLAZA, SUITE 1025, NEW YORK	/s/ Marc Panoff, Attorney-in-Fact	11 Dec 2025	0002095250

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LBRX	Employee Stock Option (Right to Buy)	Award	$0	+195,000		$0.000000	195,000	10 Dec 2025	Common Stock	195,000	$21.36	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One fourth (1/4) of the shares subject to the option award shall vest on November 10, 2026 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments on the last calendar day of each month with the first monthly installment occurring on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.